Nucleic acid encoding site specific recombinase and nuclear receptor fusion protein
First Claim
1. A fusion protein, comprising (1) a site specific recombinase protein and (2) the ligand binding domain of a nuclear receptor which is attached at the C- or N-terminus of said site specific recombinase protein, such that, in a cell or cell-free system containing DNA target sites which are specifically recognized by said site specific recombinase protein:
- (a) site specific recombinase activity of said fusion protein in relation to the DNA target sites is inhibited in the absence of ligand binding to said ligand binding domain, and(b) inhibition of said site specific recombinase activity of said fusion protein in relation to the DNA target sites is relieved by binding of ligand to said ligand binding domain.
1 Assignment
0 Petitions
Accused Products
Abstract
An invention is described that permits the regulation of recombination in cells, organisms or appropriate cell-free systems. The invention involves creating fusion proteins between recombinase proteins, or components of recombinase systems, and ligand binding domains derived from nuclear receptors. The fusion proteins show little recombinase activity in the absence of the ligand that binds to the ligand binding domain. Upon binding of the ligand, recombinase activity is induced. The invention provides a practical means to regulate recombination in cells and organisms and, by linking ligand binding to recombination, provides a simple means whereby ligand binding can be measured as recombination achieved.
-
Citations
15 Claims
-
1. A fusion protein, comprising (1) a site specific recombinase protein and (2) the ligand binding domain of a nuclear receptor which is attached at the C- or N-terminus of said site specific recombinase protein, such that, in a cell or cell-free system containing DNA target sites which are specifically recognized by said site specific recombinase protein:
-
(a) site specific recombinase activity of said fusion protein in relation to the DNA target sites is inhibited in the absence of ligand binding to said ligand binding domain, and (b) inhibition of said site specific recombinase activity of said fusion protein in relation to the DNA target sites is relieved by binding of ligand to said ligand binding domain. - View Dependent Claims (2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15)
-
-
8. The plasmid pHFE1 (DSM 9265).
Specification